322 related articles for article (PubMed ID: 19686384)
21. Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease.
Park JY; Paik SR; Jou I; Park SM
Glia; 2008 Aug; 56(11):1215-23. PubMed ID: 18449945
[TBL] [Abstract][Full Text] [Related]
22. Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation.
Shaikh S; Nicholson LF
J Neurosci Res; 2008 Jul; 86(9):2071-82. PubMed ID: 18335520
[TBL] [Abstract][Full Text] [Related]
23. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
24. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein.
Tsigelny IF; Bar-On P; Sharikov Y; Crews L; Hashimoto M; Miller MA; Keller SH; Platoshyn O; Yuan JX; Masliah E
FEBS J; 2007 Apr; 274(7):1862-77. PubMed ID: 17381514
[TBL] [Abstract][Full Text] [Related]
25. Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA.
Becker K; Wang X; Vander Stel K; Chu Y; Kordower J; Ma J
Mol Neurobiol; 2018 Nov; 55(11):8728-8737. PubMed ID: 29589283
[TBL] [Abstract][Full Text] [Related]
26. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity.
Liu G; Zhang C; Yin J; Li X; Cheng F; Li Y; Yang H; Uéda K; Chan P; Yu S
Neurosci Lett; 2009 May; 454(3):187-92. PubMed ID: 19429081
[TBL] [Abstract][Full Text] [Related]
27. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
[TBL] [Abstract][Full Text] [Related]
28. The good and bad of therapeutic strategies that directly target α-synuclein.
Longhena F; Faustini G; Brembati V; Pizzi M; Bellucci A
IUBMB Life; 2020 Apr; 72(4):590-600. PubMed ID: 31693290
[TBL] [Abstract][Full Text] [Related]
29. Impairment of microtubule system increases alpha-synuclein aggregation and toxicity.
Kim M; Jung W; Lee IH; Bhak G; Paik SR; Hahn JS
Biochem Biophys Res Commun; 2008 Jan; 365(4):628-35. PubMed ID: 18022384
[TBL] [Abstract][Full Text] [Related]
30. Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology.
Ikeda M; Kawarabayashi T; Harigaya Y; Sasaki A; Yamada S; Matsubara E; Murakami T; Tanaka Y; Kurata T; Wuhua X; Ueda K; Kuribara H; Ikarashi Y; Nakazato Y; Okamoto K; Abe K; Shoji M
Brain Res; 2009 Jan; 1250():232-41. PubMed ID: 18992718
[TBL] [Abstract][Full Text] [Related]
31. Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease.
Kazantsev AG; Kolchinsky AM
Arch Neurol; 2008 Dec; 65(12):1577-81. PubMed ID: 19064744
[TBL] [Abstract][Full Text] [Related]
32. Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors.
Krenz A; Falkenburger BH; Gerhardt E; Drinkut A; Schulz JB
J Neurochem; 2009 Jan; 108(1):139-46. PubMed ID: 19094062
[TBL] [Abstract][Full Text] [Related]
33. FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T.
Gerard M; Debyser Z; Desender L; Baert J; Brandt I; Baekelandt V; Engelborghs Y
J Neurochem; 2008 Jul; 106(1):121-33. PubMed ID: 18346205
[TBL] [Abstract][Full Text] [Related]
34. Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes.
Gustafsson G; Lindström V; Rostami J; Nordström E; Lannfelt L; Bergström J; Ingelsson M; Erlandsson A
J Neuroinflammation; 2017 Dec; 14(1):241. PubMed ID: 29228971
[TBL] [Abstract][Full Text] [Related]
35. Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers.
Vaikath N; Sudhakaran I; Abdi I; Gupta V; Majbour N; Ghanem S; Abdesselem H; Vekrellis K; El-Agnaf O
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498957
[TBL] [Abstract][Full Text] [Related]
36. The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers.
Näsström T; Wahlberg T; Karlsson M; Nikolajeff F; Lannfelt L; Ingelsson M; Bergström J
Biochem Biophys Res Commun; 2009 Jan; 378(4):872-6. PubMed ID: 19070597
[TBL] [Abstract][Full Text] [Related]
37. Cellular response of human neuroblastoma cells to α-synuclein fibrils, the main constituent of Lewy bodies.
Pieri L; Chafey P; Le Gall M; Clary G; Melki R; Redeker V
Biochim Biophys Acta; 2016 Jan; 1860(1 Pt A):8-19. PubMed ID: 26468903
[TBL] [Abstract][Full Text] [Related]
38. On the mechanism of internalization of alpha-synuclein into microglia: roles of ganglioside GM1 and lipid raft.
Park JY; Kim KS; Lee SB; Ryu JS; Chung KC; Choo YK; Jou I; Kim J; Park SM
J Neurochem; 2009 Jul; 110(1):400-11. PubMed ID: 19457104
[TBL] [Abstract][Full Text] [Related]
39. Facile "stop codon" method reveals elevated neuronal toxicity by discrete S87p-α-synuclein oligomers.
Ha Y; Yang A; Lee S; Kim K; Liew H; Suh YH; Park HS; Churchill DG
Biochem Biophys Res Commun; 2014 Jan; 443(3):1085-91. PubMed ID: 24380864
[TBL] [Abstract][Full Text] [Related]
40. Suppression, disaggregation, and modulation of γ-Synuclein fibrillation pathway by green tea polyphenol EGCG.
Roy S; Bhat R
Protein Sci; 2019 Feb; 28(2):382-402. PubMed ID: 30394624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
